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Abstract
Background: Bioluminescent imaging (BLI) is based on the detection of light emitted by living cells
expressing a luciferase gene. Stable transfection of luciferase in cancer cells and their inoculation
into permissive animals allows the noninvasive monitorization of tumor progression inside internal
organs. We have applied this technology for the development of a murine model of colorectal
cancer involving the liver, with the aim of improving the pre-clinical evaluation of new anticancer
therapies.
Results: A murine colon cancer cell line stably transfected with the luciferase gene (MC38Luc1)
retains tumorigenicity in immunocompetent C57BL/6 animals. Intrahepatic inoculation of
MC38Luc1 causes progressive liver infiltration that can be monitored by BLI. Compared with
ultrasonography (US), BLI is more sensitive, but accurate estimation of tumor mass is impaired in
advanced stages. We applied BLI to evaluate the efficacy of an immunogene therapy approach based
on the liver-specific expression of the proinflammatory cytokine interleukin-12 (IL-12).
Individualized quantification of light emission was able to determine the extent and duration of
antitumor responses and to predict long-term disease-free survival.
Conclusion: We show that BLI is a rapid, convenient and safe technique for the individual
monitorization of tumor progression in the liver. Evaluation of experimental treatments with
complex mechanisms of action such as immunotherapy is possible using this technology.
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The liver is the most frequent site for metastases from
colorectal cancer. Approximately 10–25% of colon cancer
patients present one or multiple liver metastases at the
time of diagnose [1]. At least in 30% of these cases the
liver is the only organ affected, apart from the tumor in
the gastrointestinal tract. Moreover, recurrence after surgi-
cal removal of the primary lesion occurs mainly in the
liver, with a 20–25% rate of metachronous liver metas-
tases. Potentially curative resection of hepatic tumors is
not feasible in more than 75% of the cases due to large
size, elevated number and/or unfavourable localization of
lesions, or poor liver function. Nonsurgical approaches
including systemic chemotherapy and regional treatments
are the only options for these patients. Local control is
often achieved and these techniques are rapidly improv-
ing [2,3], but a significant increase in long-term survival is
not guaranteed. Therefore, hepatic metastases from colon
cancer are frequently observed in the clinic and they are
the most frequent cause of death in these patients.
Advances in the management of this disease will probably
require the combination of standard care and new thera-
pies that are still in the experimental stage.
Immunotherapy is one of these alternatives [4]. Systemic
or local administration of vectors driving expression of
immunostimulatory cytokines such as interleukin-12 (IL-
12) has demonstrated potent antitumor effects in pre-
clinical studies [5-8]. However, further optimization of
this approach is required, and improvement in animal
models is needed so that research in this area can generate
more clinically relevant results [9,10]. In a previous study
[11], we described a High-Capacity (gutless) adenoviral
vector carrying a liver-specific inducible system for the
expression of murine IL-12 (GL-Ad/RUmIL-12). Intrave-
nous administration of this vector eliminated intrahepatic
colon cancer in a murine model when intense production
of IL-12 was induced at early stages of the disease. If more
restrictive conditions are used (larger tumors and lower
dose of vector that leads to moderate IL-12 concentration)
the antitumor response was heterogeneous (manuscript
in preparation), as observed with many other experimen-
tal approaches [12].
In these cases, a more detailed characterization of the par-
tial responses would be desirable, and longitudinal mon-
itoring of individual subjects could identify transient
antitumor effects. Implantation of certain colon cancer
cell lines in the liver of syngeneic mice constitutes one
kind of intrahepatic cancer model [13]. Although each
model has its own limitations, progressive growth and
extra hepatic dissemination of these tumors often leads to
the death of the animal, recapitulating some aspects of the
natural history found in humans. However, monitoring
progression in these internal tumors by direct measure-
ment requires repeated laparotomy or large groups of ani-
mals to be sacrificed at different time points, thus
precluding an individualized follow-up. Different nonin-
vasive imaging techniques have been developed to over-
come these limitations. Some of them such as
ultrasonography (US) [14], computerized tomography
(CT) [15], positron emission tomography (PET) [16], sin-
gle photon emission computed tomography (SPECT) [17]
and magnetic resonance imaging (MRI) [18,19] are adap-
tations of clinical imaging devices to the use in small ani-
mals. Others such as fluorescence imaging (FLI) [20] and
bioluminescent imaging (BLI) [21,22] have been specifi-
cally developed for the in vivo monitoring of gene expres-
sion in experimental animals, mostly rodents.
Bioluminescence of cells is based on a chemical reaction
catalyzed by the luciferase enzyme in which a substrate
(D-luciferin) is converted into an excited oxyluciferin
intermediate in the presence of Oxygen, Magnesium and
ATP [23]. When oxyluciferin returns to its relaxed state, it
emits a photon in the visible wavelength range. The most
common source for luciferase is the firefly Photinus pyralis.
Since no luciferase expression is found in mammalian
cells and there is no need for external light excitation, this
method of cell labelling has a very low background. The
intensity of light is proportional to the amount of luci-
ferase expressed in each individual cell, and the number of
cells in which the gene has been transferred. In addition,
actual light detectors have a very high dynamic range.
Therefore, luciferase-based assays have been widely used
to study changes in gene expression intensity in vitro and
in vivo. For tumor imaging, a luciferase expressing gene is
transferred to cancer cells and stable clones are implanted
into permissive hosts. These can be syngeneic animals
[24-27], but in the case of human cancer cell lines, immu-
nodeficient mice or rats are required [28-32]. A cooled
charge-coupled device (CCD) camera attached to a light-
tight chamber is then used to detect the intensity and loca-
tion of light emission. The high sensitivity of BLI has been
extensively demonstrated in different tumor models,
including colon cancer [30,33]. However, stability of luci-
ferase expression and maintenance of a good correlation
between light emission and tumor burden needs further
investigation, especially if orthotopic (intrahepatic)
immunocompetent models are used [26,27]. The influ-
ence of anatomical barriers and the fact that luciferase is a
foreign gene could interfere with this correlation. There-
fore, in this study we have stably transfected MC38
murine colon cancer cells with a plasmid carrying luci-
ferase gene and have monitored the evolution of biolumi-
nescence and tumor volume after subcutaneous or
intrahepatic inoculation of cells in C57BL/6 mice. We
found a direct correlation between these two parameters
in both cases, although higher dispersion was observed at
late stages of the experiment. Long-term maintenance ofPage 2 of 13
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Molecular Cancer 2009, 8:2 http://www.molecular-cancer.com/content/8/1/2the genetically modified cells and stability of luciferase
expression were observed.
In addition, we provide evidence showing that this model
is suitable for evaluation of individual responses to
immunotherapy. Using BLI monitoring, we were able to
identify subsets of animals that experienced transient
reduction in tumor progression, and to clearly distinguish
this group from others having no effect, or long-term
complete responses.
Results and discussion
Characterization of MC38 colon cancer cells stably 
transfected with the luciferase gene
MC38 cells were transfected with a plasmid carrying luci-
ferase under the control of the CMV promoter, and 10 dif-
ferent clones were isolated after antibiotic selection. As
expected, clones varied in their specific luciferase activity
(measured by standard luminometer -data not shown-).
In figure 1A we represent light emission in living cells cor-
responding to 3 clones after incubation of increasing
number of cells with the substrate D-luciferin. Clone
number 1 (MC38Luc1) was chosen for further characteri-
zation because it presented the highest luciferase activity.
We determined that at least 500 MC38Luc1 cells are
required to obtain a luminescence significantly higher
than background (3,590 +/- 1,275 versus 1,900 +/- 1,300
photons/s, respectively). Intense light emission was main-
tained for at least 40 passages in vitro, as shown in figure
1B. A transient increase in the specific luciferase activity
(photons/s/cell) was observed until passage 30, with fur-
ther stabilization (figure 1B). This rules out the possibility
that the CMV promoter is inhibited over time in the
MC38Luc1 clone. Luciferase expression was analyzed by
immunocytochemistry (figure 1C) in order to verify that
the transgene is expressed in all individual cells at late pas-
sages. The lack of negative cells supports the absence of
promoter silencing.
Characterization of the MC38Luc1 cell lineFigure 1
Characterization of the MC38Luc1 cell line. A.-Three independent MC38Luc clones were seeded in 96-well plates at dif-
ferent cell densities, and incubated with the luciferase substrate D-luciferin. Light emission from living cells in each well was 
immediately quantified using a CCD camera. The horizontal discontinuous line indicates the background light emission of an 
empty well. B. – The same procedure was used to quantify light emission from clone 1 (MC38Luc1) after maintenance in vitro 
for at least 40 passages. C. – Expression of luciferase was detected in MC38Luc1 cells at passage 30 by immunocytochemistry 
(right panel). Left panel corresponds to the parental MC38 cells. Magnification 400×. D. – MC38Luc1 or the parental MC38 
cells (106 per mouse) were injected subcutaneously in the right hind flank of C57BL/6 mice (n = 10) to compare tumorigenicity. 
Tumor volumes achieved 3 weeks after cell implantation are shown. Error bars represent standard deviations.
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tumorigenic properties of the parental cells, we inoculated
106 MC38 or MC38Luc1 cells subcutaneously in two
groups of C57BL/6 mice. We could not detect any differ-
ence in tumor progression between both groups. In figure
1D, we represent the average tumor volume 3 weeks after
inoculation of cells, determined by direct calliper meas-
urement. Therefore, integration of the luciferase expres-
sion cassette in the genome of the MC38Luc1 clone did
not change their ability to form tumors in vivo. In a previ-
ous report by an independent group [33], MC38 cells
transduced with retroviruses encoding luciferase or GFP
showed moderate differences in tumor progression,
although both cell lines gave rise to tumors that grew pro-
gressively for at least 20 days. The size of tumors observed
in our experiments (367 mm3 after 21 days) coincides
remarkably with the clone described by Choy et al [33].
This and other studies in syngeneic animals clearly dem-
onstrate that tumor cells expressing luciferase are not
selectively eliminated by the immune system.
Comparison of US and BLI for noninvasive monitorization 
of liver metastases
We inoculated 5 × 105 MC38Luc1 cells in the liver of
C57BL/6 mice and monitored tumor progression by BLI
or US. Subsets of animals in the group were laparot-
omized or sacrificed at one week intervals for direct calli-
per measurement of tumor diameters. In figure 2A, we
Monitorization of hepatic tumors by BLI and USFigure 2
Monitorization of hepatic tumors by BLI and US. A.-MC38Luc1 cells were injected in the liver of C57BL/6 mice (n = 
20), and tumor progression was evaluated weekly by either BLI (bottom pictures), US (middle pictures) or direct tumor meas-
urement through laparotomy or necropsy (upper pictures). Margins of tumors are indicated with a dotted line in the US 
images. B.-Example of lung metastases secondary to the hepatic lesions 4 weeks after cell implantation in the liver. Detection 
by BLI (bottom picture) and confirmation after necropsy (upper picture).
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identified by the three methods at different stages of the
disease. Both BLI and US were able to detect the presence
and localization of lesions, and to assess their progression
over time. US was less sensitive and could not detect the
small tumors rising one week after cell injection. How-
ever, this technique provided more anatomical informa-
tion about tumor spread and involvement of other
organs. As expected, BLI had lower spatial resolution, but
it was able to indicate the approximate location and size
of tumors in most of the cases, apart from the light emis-
sion quantification. In fact, in those few animals that sur-
vived more than 5 weeks, lung metastases usually
occurred and could be detected by BLI (figure 2B). Finally,
BLI is faster (at least 10 mice can be analyzed at a time in
less than 20 minutes) and requires less technical training
than US. In order to validate the noninvasive imaging of
liver metastases, we analyzed the correlation between BLI,
US and direct tumor measurement. In figure 3A we show
the progression of the average tumor volume determined
by laparotomy or US, as well as the luciferase activity
(light emission in photons/s). From this comparison, we
can see that tumor progression can be monitored using
both BLI and US. In agreement with previous results from
other groups [22], BLI is the most sensitive technique,
because tumor cells can be detected as early as 2 days after
implantation, before they form macroscopic tumors. The
maximum background light emission detected in a non-
tumor bearing animal was 10,000 photons/s, approxi-
mately 10 times less than the average emission of
MC38Luc1-injected animals. US started to detect hepatic
lesion 2 weeks later. In our experience, tumor diameters
determined by US are smaller than those obtained by
direct calliper measurement and therefore the estimated
volume of tumors is reduced. We believe this is due to the
restrictive criteria used to define tumor margins in the US
and does not affect the validity of the technique. In fact,
correlation between tumor volumes calculated by both
methods is good (figure 3B).
Limitations of BLI in the advanced stage of tumors
Good correlation between BLI and direct tumor measure-
ment was also observed during the first 3 weeks of the
experiment. In figure 3C, we represent the values for indi-
vidual animals at day 13 after cell implantation. Later on,
when tumors became large enough to be detected by
physical examination, linear correlation was partially lost
(figure 3D). In general, this is due to a plateau in the luci-
ferase activity of tumors (figure 3A), which does not cope
with tumor growth in the later stages of the disease. To
investigate if this is specific for intrahepatic tumors, we
inoculated MC38Luc1 cells subcutaneously and analyzed
the same parameters. In figure 4A we show the average
tumor volume and light emission over time. As expected
in superficial tumors, high bioluminescence was observed
at early time points, and there was a progressive increase
following tumor growth. In terms of bioluminescence/
volume correlation, it was optimal during the first 3 weeks
(figure 4B), and then the values started to be more dis-
persed (figure 4C). Therefore, the same trend is observed
in subcutaneous and hepatic tumors, although the partial
loss of correlation is more obvious in the hepatic lesions,
probably because they grow faster. This suggests that BLI
is less reliable to assess tumor burden in advanced stages
of the disease, when tumors approach their maximum
size. Nevertheless, it can be useful to determine non-inva-
sively a criteria for animal sacrifice before they reach the
undesirable situation of extremely large lesions, thus con-
tributing to the refinement of intrahepatic tumor models.
In this case, it seems that light emission higher than 2.5 ×
107 photons/s could be considered a reasonable limit.
It is not clear at this moment if the limitations of BLI in
large tumors can be considered a general characteristic of
this technique. The observation periods described in the
literature are heterogeneous, and the time to reach the
"advanced stage" differs in each tumor model. Neverthe-
less, attenuation of luciferase signal has been previously
described in another colorectal cancer liver metastasis
model developed in Balb/c mice [27]. A partial loss of cor-
relation between BLI and physical measurement was
found in large tumors starting on day 20 after cell inocu-
lation, which is similar to our observations. In this case
the main reason was the quenching effect of the ascitic
fluid, which is usually abundant in advanced CT26
tumors growing in the liver. Accumulation of large vol-
umes of hemorrhagic ascites was less frequent in our int-
rahepatic MC38Luc1 tumors. In addition, this factor
cannot play a role in the subcutaneous tumors described
here. In a different study, a marked inhibition of biolumi-
nescence was found in a bladder cancer model, starting 2
weeks after cell implantation [34]. The authors demon-
strated a reduction in light emission from necrotic and
hemorrhagic areas of the tumors. In addition, these areas
can contribute to the quenching effect of surrounding tis-
sues. If the proportion of these inactive fractions of the
tumor increases over time and is more prevalent in large
tumors, this is a feasible explanation for the loss of corre-
lation between bioluminescence and tumor volume. In
our model, histological analysis of tumors revealed varia-
ble regions of necrosis and haemorrhage. However, when
we studied individual tumors, we could not establish a
direct correlation between the abundance of these areas
and the decline of light emission (data not shown). There-
fore, other factors may play a role in this phenomenon.
We have verified by quantitative PCR that there is no
decrease in the frequency of luciferase plasmids integrated
in the tumors at different time points. As shown in figure
5A, we found an average of approximately 4 copies of
plasmid for every copy of the endogenous albumin genePage 5 of 13
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Molecular Cancer 2009, 8:2 http://www.molecular-cancer.com/content/8/1/2(which means 2 copies per genome) even in the very
advanced stage (day 28). This indicates that the
MC38Luc1 cells do not lose the luciferase gene over time
in vivo, and the proportion of these cells in the tumor mass
is maintained on average. Interestingly, the ratio of cop-
ies/genome is not randomly distributed among tumors at
day 28 (figure 5B). We observed that larger tumors tend to
present less copies of luciferase plasmid per genome, sug-
gesting that stromal cells (fibroblasts, endothelial cells,
etc.), which do not contribute to the luciferase expression
are more abundant in these tumors. These luciferase-inac-
tive components of the tumors, together with areas of
necrosis and haemorrhage are mixed in variable propor-
tions and impair an accurate determination of tumor vol-
ume by BLI. Therefore, in advanced stages of our tumor
model, the functional information obtained by BLI pre-
vails over the morphological criteria.
Hypoxia has been recently proposed as a potential inhib-
itor of the luciferase reaction [35]. Experiments performed
in vitro demonstrated that intense hypoxia (0,2% pO2)
can reduce ATP levels in cells and impair biolumines-
cence. Differences in the extension and intensity of
hypoxic areas could contribute to the lack of correlation
between light emission and tumor volume. To investigate
this possibility, we obtained lysates from advanced
tumors and performed in vitro luciferase reactions. Under
these circumstances, luciferase activity (measured in Rela-
tive Luciferase Units, RLUs in a standard luminometer)
only depends on the amount of functional enzyme,
Correlation between BLI, US and direct tumor volume determination in hepatic tumorsFigure 3
Correlation between BLI, US and direct tumor volume determination in hepatic tumors. MC38Luc1 cells (5 × 
105) were injected in the liver of C57BL/6 mice (n = 20), and tumor progression was evaluated weekly by either BLI, US or 
direct tumor measurement through laparotomy or necropsy. A – Tumor volume determined by direct measurement (calliper, 
black circles) or US (black squares) over time. Volumes are indicated in the left Y axis. Light emission quantified by BLI is rep-
resented as a dotted line and the scale corresponds to (photons/s) × 103 in the right Y axis. Error bars represent standard devi-
ations. B.-Correlation between tumor volumes determined by US (X axis) and direct measurement after necropsy (calliper, Y 
axis) one month after cell implantation. C-D – Correlation between light emission and direct tumor measurement 2 weeks (C) 
or 3 weeks (D) after cell implantation (log10 conversion of values).
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Correlation between BLI and direct tumor volume determination in subcutaneous tumorsFigure 4
Correlation between BLI and direct tumor volume determination in subcutaneous tumors. MC38Luc1 cells (106) 
were injected subcutaneously in the right hind flank of C57BL/6 mice (n = 14), and tumor progression was evaluated weekly by 
either BLI or direct measurement. A – Monitorization of tumor volume by direct measurement (calliper, black circles) corre-
sponds to the left Y axis. Light emission quantified by BLI is represented as a dotted line and the scale corresponds to photons/
s × 103 in the right Y axis. Error bars represent standard deviations. C-D – Correlation between light emission and direct 
tumor measurement 2 weeks (C) or 4 weeks (D) after cell implantation (log10 conversion of values).
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Analysis of luciferase stability and function in vivoFigure 5
Analysis of luciferase stability and function in vivo. A. – Intrahepatic MC38Luc1 tumors (n = 10) were excised at differ-
ent times after cell implantation (2, 3 and 4 weeks), and the relative copy number of the plasmid pCDNA3-luc was determined 
by qPCR. The values correspond to the number of plasmid copies divided by the copies of the endogenous albumin gene. Error 
bars represent standard deviations. B. – Correlation between the relative pCDNA3-luc copy number in advanced tumors (4 
weeks after implantation) and tumor volume. C. – Correlation between in vivo light emission of advanced tumors (in photons/
sec.) and luciferase activity (in RLUs) obtained in solution from tumor extracts (log10 conversion of values).
Molecular Cancer 2009, 8:2 http://www.molecular-cancer.com/content/8/1/2because all other components of the reaction, including
ATP, are contained in the assay buffer. Therefore, if lack of
ATP is limiting light emission in some of the MC38Luc1
tumors in vivo, luciferase activity should be restored in
vitro. However, we did not observe any sample in which
low photon emission in vivo was accompanied by an
unexpectedly high RLU value in vitro (figure 5C). This sug-
gests that hypoxia is not interfering with BLI in the
MC38Luc1 model. However, the correlation between
both parameters was modest (r2 = 0.42) due to considera-
ble dispersion of values. Therefore, we cannot definitely
rule out the possibility that availability of ATP in vivo is
affecting the accuracy of BLI.
Validity of BLI to monitor the efficacy of immunotherapy
The ability of BLI to evaluate the efficacy of conventional
[24] or experimental [30,31] treatments has been demon-
strated in different tumor models, but little is known
about immunotherapy approaches in syngeneic mice. We
have previously described a potent antitumor effect of the
high-capacity adenoviral vector GL-Ad/RUmIL-12 on int-
rahepatic MC38-derived tumors [11]. A liver-specific,
Mifepristone-inducible expression system allows control-
led expression of IL-12. The vector was administered one
week before cell implantation, and activation of IL-12
expression started 5 days later. Under these circumstances,
tumor eradication was observed in most of the animals
when high doses of IL-12 were achieved. Now we aim to
evaluate the efficacy of GL-Ad/RUmIL-12 in a more
restrictive setting. BLI was used with the objective of deter-
mining the onset and duration of the antitumor response
in each animal. In the actual protocol, tumor cells
(MC38Luc1) were implanted before administration of the
virus. Initial BLI performed 48 hours after cell inoculation
allowed us to verify the localization of cells in the liver
area and the homogeneity of experimental groups in
terms of light emission (figure 6A). The next day, a mod-
erate dose of GL-Ad/RUmIL-12 vector (2.5 × 108 iu) was
administered intravenously, and induction of IL-12
expression started one week later. Therefore, tumors had
progressed for 10 days before the treatment effectively
started. The induction regime consisted on 10 daily injec-
tions of 250 μg/kg Mifepristone intraperitoneally, as pre-
viously described [11]. The average concentration of IL-12
in serum was 27 ng/ml after the first mifepristone admin-
istration, which is consistent with the dose of virus used.
Bioluminescence quantification detected significant dif-
ferences between the control and treated groups as early as
7 days after initiation of IL-12 expression (day 17 after cell
inoculation, figure 6A). More importantly, subsequent
BLI monitorization (figure 6B) allowed us to distinguish
3 subsets of animals inside the treatment group: non-
responders (NR), in which light emission was similar to
the control group; mice showing a partial response (PR)
consisting in a transient inhibition of luciferase activity;
and finally others in which the signal was completely and
permanently abolished (CR). All animals that survived
long enough were laparotomized 4 weeks after initiation
of the experiment in order to determine the size of liver
tumors by direct calliper measurement. As shown in figure
6C, stratification of mice according to bioluminescence
was in accordance with the changes observed in tumor
volume. In the PR group, a significant reduction was
observed during the 4th week of the experiment, but the
tumors progressed and all animals finally died during the
next 4 weeks because of their hepatic lesions. In contrast,
mice in the CR group remained tumor-free and were neg-
ative for luciferase activity for the entire duration of the
experiment (more than 6 months).
Conclusion
We have validated an immunocompetent model of
hepatic tumors that allows the noninvasive monitoriza-
tion of tumor progression using BLI. A good correlation
between functional imaging and tumor volume was
observed until mice reached an advanced stage of the dis-
ease. This model is suitable to characterize transient and
long-term antitumor responses obtained with new thera-
peutic approaches such as immunotherapy.
Methods
Cell lines
The MC38 murine colon carcinoma cell line was derived
from 3-methylcholanthrene-treated C57BL/6 mice [36]. It
was grown in Dulbecco's modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 100 μg/ml streptomycin and 100 μg/
ml penicillin (all from of Gibco, Invitrogen) and 2 mM
glutamine (Cambrex). The MC38Luc1 clone was main-
tained in the same media supplemented with 400 μg/ml
G418 (geneticin, Gibco, Invitrogen).
DNA cloning and stable transfection
pCDNA3-luc was generated by inserting the luciferase gene
from the plasmid pGL3-Basic (Promega) into the HindIII-
XbaI sites of pCDNA3.1 vector (Invitrogen). MC38 cells
were grown in 10 cm dishes and were transfected with 4
μg of pCDNA3-luc by the calcium phosphate precipita-
tion method when they reached 50–60% confluence.
Post-transfection culture medium was replaced 16 hours
later by DMEM 10% FBS supplemented with 400 μg/ml
G418. Resistant clones were isolated by individual
trypsinization and expanded.
Bioluminescence imaging
Different clones transfected with the pCDNA3-luc plas-
mid were plated in 96 well-black plates (Packard) at a
density of 100; 500; 1,000; 5,000; 12,500; 25,000;
50,000; 75,000 or 100,000 cells per well for MC38Luc1
cells, or at cell densities above 12,500 cell/well for clonesPage 9 of 13
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Antitumor effect of IL-12 monitored by BLIFigure 6
Antitumor effect of IL-12 monitored by BLI. MC38Luc1 cells (5 × 105) were injected in the liver of C57BL/6 mice (n = 
26). After verification of cell engraftment, the vector GL-Ad/RUmIL-12 was injected intravenously at 2.5 × 108 iu/mouse in half 
of the mice, and IL-12 expression was activated by mifepristone one week later. A. – Quantification of light emission before 
virus injection (day 2) and 7 days after initiation of IL-12 expression (day 17) in control (Co) and treated groups (IL-12). B. – 
Monitoring of tumor progression by BLI. Control group is represented as a dotted line. Three subgroups were defined among 
treated animals: non-responders (NR), mice with partial response (PR) and complete response (CR). Differences were statisti-
cally significant (p < 0.01) between Co and PR groups during days 20 to 30. Light emission from the CR group remained signif-
icantly lower until the end of the experiment. C. – Average tumor volume of the different groups one month after cell 
implantation, and at the time of sacrifice or spontaneous death. No evidence of tumor was observed in the CR group. Error 
bars represent standard deviations. * p < 0.05; ** p < 0.01.
Molecular Cancer 2009, 8:2 http://www.molecular-cancer.com/content/8/1/2MC38Luc4 and MC38Luc8. Twenty-four hours later, cells
were washed in PBS and D-luciferin substrate (Promega)
was added at a final concentration of 150 μg/ml. Light
emission from culture plates was detected immediately
using the IVIS CCD camera system (Xenogen) and ana-
lyzed with the Living Image 2.20 software package (Xeno-
gen). For in vivo imaging and quantification of light
emission, mice were anesthetized with a mixture of Xyla-
cine and Ketamine and 150 mg/kg D-luciferin (100 μl of
a 30.3 mg/ml solution dissolved in phosphate-buffered
saline) were injected intraperitoneally. Ten minutes later,
animals were placed in the dark chamber for light acqui-
sition. Typically, a circular region of interest measuring 3
cm in diameter was defined in the abdomen of mice, and
quantification of light emission was performed in pho-
tons/second. Time exposure ranged from 1 second to 5
minutes depending on light intensity. A maximum of 10
animals were analyzed at a time.
Determination of luciferase activity in solution
Fifty to 150 mg of frozen tumor samples were lysed in
Reporter Lysis Buffer (Promega) and centrifuged at 13.000
rpm in a cooled microfuge for 10 minutes. The luciferase
activity was measured in the supernatant using the Luci-
ferase Reporting Assay System (Promega) in a Berthold
microplate luminometer. The luciferase Relative Lights
Units (RLUs) obtained for each sample were multiplied
by the total tumor weight to obtain an estimation of the
RLU/tumor.
RNA and genomic DNA isolation and qRT-PCRs
Genomic DNA and total RNA was extracted from 50–100
mg frozen tumor samples using QIAmp DNA mini kit only
(Qiagen) or TRI reagent (Sigma), respectively, following
manufacturer's instructions. Three μg of RNA were treated
with DNase I and retro transcribed to cDNA with M-MLV RT
in the presence of RNase out reagent (all from Invitrogen).
For real time PCR reactions, 2 μl of genomic DNA or cDNA
were mixed with specific primers using iQ SYBR Green
Supermix (Bio-Rad). Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used to normalize gene expression
and murine albumin was used to normalize genomic DNA
content. Gene expression (specific mRNA content) is repre-
sented by the formula 2ΔCt where ΔCt indicates the difference
in the threshold cycle between GAPDH and luciferase. Plas-
mid copy number refers to the copies of the neo resistance
gene relative to the copies of the endogenous albumin gene.
Standard curves were used to calculate copy numbers in each
case. The name and sequence of primers used is as follows:
GAPDH forward CCAAGGTCATCCATGACAAC; reverse
TGTCATACCAGGAAATGAGC. Albumin forward GATGCT-
GCTCTTTGGCTATGA; reverse CAGCAGTCAGCCAGT-
TCACC Neo forward AGATGGATTGCACGCAGGT; reverse
TTGCATCAGCCATGATGGA. Firefly Luciferase forward
AGAGATACGCCCTGGTTC; reverse ATAAATAACGCGCC
CAACAC.
Immunohistochemistry
MC38 and MC38Luc1 cells were cultured in glass cov-
erslides and fixed in pre-chilled acetone for 4 min. Sam-
ples were kept at -20°C before being analyzed. For
luciferase protein detection, coverslides were air-dried and
washed tree times in phosphate-buffered saline (PBS).
Endogenous peroxidase was quenched with Peroxidase
Blocking Reagent (DAKO) for 15 min at room tempera-
ture. Samples were then washed and incubated with 5 μg/
ml of the primary goat anti-luciferase antibody (Cortex)
for 1 h at room temperature. After additional washing,
samples were incubated with the polyclonal biotinylated
anti-goat antibody diluted 1:600 in PBS for 45 min and
then were incubated for 45 min with HRP-streptavidin
(Amersham). The peroxidase activity was revealed using
DAB Substrate Chromogen System (DAKO).
Mice and tumor cell inoculation
Five to 8 weeks old C57BL/6J female mice were purchased
from Harlan (Barcelona, Spain) and were kept in the ani-
mal facility at least one week before starting the experi-
ments. Tumors were established by subcutaneous (s.c.) or
intrahepatic (i.h.) implantation of cells. For s.c. tumor for-
mation, a total of 106 cells were injected in the right hind
flank. For liver metastases establishment, 5 × 105 cells
were injected into the left liver lobe of mice following
medial laparotomy in isofluorane-anesthesized animals.
In both cases, cells were resuspended in a total volume of
50 μl saline solution. Tumor size was monitored at indi-
cated time points measuring two perpendicular tumor
diameters using a precision calliper. Tumor volume was
calculated using the following formula: V = length ×
width2 × 0.5. In the case of intrahepatic tumors, laparoto-
mies were performed in a subset of the animals at weekly
intervals in order to estimate the average tumor volume of
the group by direct calliper measurement. Individual ani-
mals underwent a maximum of two exploratory laparoto-
mies before they were sacrificed. Survival was checked
daily and mice were euthanized if general status was dete-
riorated. All in vivo experiments were performed in accord-
ance with the local animal commission.
Ultrasonography
Mice were anesthetized with 1.5% isofluorane in oxygen
at 0.6 L/min delivered via nose cone and allowed to
breathe spontaneously. They were placed in supine posi-
tion on a feedback-controlled heating pad. Abdomen was
shaved, and pre-warmed ultrasound gel was applied on
the skin of mice. Recordings were made under continuous
ECG monitoring by fixing the electrodes on the limbs.
Two-dimension mode U.S imaging was performed byPage 11 of 13
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unit (VEVO 770; Visualsonics, Toronto, Canada) and a
Visualsonics RMV 700-series scanhead with a 30–40 MHz
high frequency linear transducer (depth of field 1.5–2.2
mm, field of view-max 14.5–16.5 mm). Tumor diameter
measurements were made from digital images captured
on cineloops at the time of the study using the software
incorporated in the VEVO 770 device. Tumor volumes
were calculated as described in the previous section.
Treatment of colorectal liver metastases by adenoviral-
directed expression of IL-12
The High-Capacity (gutless) adenoviral vector GL-Ad/
RUmIL-12 carrying a liver-specific Mifepristone-inducible
system for the expression of murine IL-12 has been previ-
ously described [11]. MC38Luc1 cells were inoculated in
the liver of C57BL/6 mice, and 3 days later 2.5 × 108 iu of
the virus were injected intravenously dissolved in 200 μl
saline solution. One week later, expression of IL-12 was
activated by daily intraperitoneal injection of 250 μg/kg
Mifepristone for 10 days. Quantification of IL-12 concen-
tration in the serum of animals was performed by ELISA
10 hours after the first induction. Tumor progression was
monitored by BLI or direct tumor measurement following
laparotomy or necropsy.
Statistical analysis
We used GraphPad Prism software for statistical analysis.
Two-tailed unpaired t-test was used to compare groups of
values when n>10. For smaller groups, Mann-Whitney
non-parametric test was used.
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